EBITDA Summary of ResMed Inc.

ResMed Inc.'s latest annual EBITDA in 2024 was 1.6 Billion USD , up 12.86% from previous year.
ResMed Inc.'s latest quarterly EBITDA in 2024 FY was N/A , up 19.47% from previous quarter.
ResMed Inc. reported an annual EBITDA of 1.35 Billion USD in 2023, up 12.18% from previous year.
ResMed Inc. reported an annual EBITDA of 1.17 Billion USD in 2022, up 7.33% from previous year.
ResMed Inc. reported a quarterly EBITDA of 435.97 Million USD for 2024 Q4, down -1.68% from previous quarter.
ResMed Inc. reported a quarterly EBITDA of N/A for 2024 FY, up 19.47% from previous quarter.

Annual EBITDA Chart of ResMed Inc. (2024 - 1993)

Historical Annual EBITDA of ResMed Inc. (2024 - 1993)

Year	EBITDA	EBITDA Growth
2024	1.6 Billion USD	12.86%
2023	1.35 Billion USD	12.18%
2022	1.17 Billion USD	7.33%
2021	1.09 Billion USD	12.4%
2020	990.43 Million USD	17.35%
2019	705.79 Million USD	20.73%
2018	680.22 Million USD	16.48%
2017	568.88 Million USD	10.96%
2016	522.71 Million USD	9.36%
2015	482.29 Million USD	15.63%
2014	484.86 Million USD	17.13%
2013	469.78 Million USD	17.59%
2012	422.58 Million USD	7.1%
2011	374.32 Million USD	16.74%
2010	322.15 Million USD	22.17%
2009	190.31 Million USD	-0.58%
2008	204.83 Million USD	49.22%
2007	90.16 Million USD	-21.8%
2006	174.04 Million USD	18.56%
2005	136.89 Million USD	43.8%
2004	85.36 Million USD	32.76%
2003	79.82 Million USD	272.76%
2002	-40.83 Million USD	-166.06%
2001	52.16 Million USD	73.16%
2000	39.38 Million USD	24.71%
1999	29.9 Million USD	40.81%
1998	21 Million USD	175.31%
1997	10.9 Million USD	305.0%
1996	4.9 Million USD	-16.67%
1995	3.4 Million USD	118.18%
1994	1.6 Million USD	266.67%
1993	900 Thousand USD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	456.92 Million USD	14.68%
2024 Q4	435.97 Million USD	-1.68%
2024 FY	- USD	19.47%
2024 Q3	429.22 Million USD	9.3%
2024 Q1	288.99 Million USD	5.04%
2023 FY	- USD	12.18%
2023 Q3	347.04 Million USD	1.31%
2023 Q4	333.76 Million USD	-3.83%
2023 Q2	342.55 Million USD	7.13%
2023 Q1	319.77 Million USD	6.45%
2022 Q1	309.53 Million USD	7.73%
2022 Q3	285.87 Million USD	-4.17%
2022 FY	- USD	7.33%
2022 Q4	300.4 Million USD	5.08%
2022 Q2	298.31 Million USD	-3.62%
2021 FY	- USD	12.4%
2021 Q4	287.31 Million USD	5.9%
2021 Q2	287.13 Million USD	7.63%
2021 Q1	266.78 Million USD	-0.73%
2021 Q3	271.3 Million USD	-5.51%
2020 Q3	263.96 Million USD	9.03%
2020 FY	- USD	17.35%
2020 Q4	268.75 Million USD	1.81%
2020 Q1	215.01 Million USD	-18.82%
2020 Q2	242.09 Million USD	12.59%
2019 Q2	205.35 Million USD	17.64%
2019 FY	- USD	20.73%
2019 Q4	264.86 Million USD	33.28%
2019 Q1	174.55 Million USD	-9.84%
2019 Q3	198.72 Million USD	-3.23%
2018 Q4	193.6 Million USD	3.24%
2018 FY	- USD	16.48%
2018 Q3	187.52 Million USD	6.92%
2018 Q2	175.39 Million USD	23.4%
2018 Q1	142.12 Million USD	-8.62%
2017 Q2	170.6 Million USD	39.93%
2017 Q3	151.77 Million USD	-11.04%
2017 FY	- USD	10.96%
2017 Q4	155.52 Million USD	2.48%
2017 Q1	121.92 Million USD	-18.44%
2016 Q2	143.32 Million USD	23.1%
2016 FY	- USD	9.36%
2016 Q3	131.31 Million USD	-8.37%
2016 Q4	149.48 Million USD	13.84%
2016 Q1	116.42 Million USD	-9.95%
2015 Q4	129.29 Million USD	4.5%
2015 Q3	123.72 Million USD	-3.35%
2015 Q1	113.25 Million USD	-0.25%
2015 FY	- USD	15.63%
2015 Q2	128.01 Million USD	13.03%
2014 FY	- USD	17.13%
2014 Q4	113.54 Million USD	5.96%
2014 Q1	99.29 Million USD	12.03%
2014 Q2	107.47 Million USD	8.24%
2014 Q3	107.15 Million USD	-0.29%
2013 FY	- USD	17.59%
2013 Q1	83.12 Million USD	-10.28%
2013 Q2	94.57 Million USD	13.77%
2013 Q4	88.63 Million USD	-10.13%
2013 Q3	98.63 Million USD	4.29%
2012 Q3	82.33 Million USD	31.84%
2012 FY	- USD	7.1%
2012 Q1	65.94 Million USD	-8.15%
2012 Q2	62.44 Million USD	-5.3%
2012 Q4	92.64 Million USD	12.53%
2011 Q2	69.4 Million USD	6.18%
2011 Q3	200.99 Million USD	189.61%
2011 Q4	71.8 Million USD	-64.28%
2011 FY	- USD	16.74%
2011 Q1	65.36 Million USD	-17.71%
2010 FY	- USD	22.17%
2010 Q1	65.91 Million USD	-12.58%
2010 Q2	60.04 Million USD	-8.91%
2010 Q3	62.78 Million USD	4.57%
2010 Q4	79.42 Million USD	26.51%
2009 Q3	66.59 Million USD	20.83%
2009 Q2	55.11 Million USD	6.01%
2009 Q4	75.4 Million USD	13.23%
2009 Q1	51.99 Million USD	3.96%
2009 FY	- USD	-0.58%
2008 Q1	51.01 Million USD	9.29%
2008 FY	- USD	49.22%
2008 Q4	50.01 Million USD	-4.45%
2008 Q3	52.34 Million USD	2.6%
2008 Q2	51.01 Million USD	0.01%
2007 Q1	46.59 Million USD	-7.39%
2007 Q2	52.66 Million USD	13.02%
2007 FY	- USD	-21.8%
2007 Q4	46.67 Million USD	620.65%
2007 Q3	-8.96 Million USD	-117.02%
2006 Q3	47.41 Million USD	14.36%
2006 Q4	50.31 Million USD	6.12%
2006 Q2	41.45 Million USD	15.25%
2006 Q1	35.97 Million USD	-19.81%
2006 FY	- USD	18.56%
2005 Q2	33.67 Million USD	9.73%
2005 Q1	30.69 Million USD	2.41%
2005 FY	- USD	43.8%
2005 Q4	44.86 Million USD	18.02%
2005 Q3	38.01 Million USD	12.87%
2004 Q1	23.72 Million USD	20.09%
2004 Q2	22.01 Million USD	-7.22%
2004 FY	- USD	32.76%
2004 Q4	29.97 Million USD	10.9%
2004 Q3	27.02 Million USD	22.76%
2003 Q2	19.3 Million USD	1.12%
2003 Q3	20.49 Million USD	-1.75%
2003 Q4	21.54 Million USD	3.51%
2003 FY	- USD	272.76%
2003 Q1	18.48 Million USD	120.77%
2002 FY	- USD	-166.06%
2002 Q3	15.44 Million USD	-0.47%
2002 Q1	15.71 Million USD	73.6%
2002 Q2	16 Million USD	3.1%
2002 Q4	-88 Million USD	-677.73%
2001 Q4	9.67 Million USD	-73.48%
2001 FY	- USD	73.16%
2001 Q3	16.1 Million USD	208.04%
2001 Q2	11.57 Million USD	7.98%
2001 Q1	11.07 Million USD	2.34%
2000 Q2	10 Million USD	17.98%
2000 Q3	10.21 Million USD	-7.77%
2000 Q4	10.28 Million USD	2.8%
2000 FY	- USD	24.71%
2000 Q1	8.84 Million USD	-5.32%
1999 Q1	6.3 Million USD	-10.53%
1999 Q2	7.1 Million USD	4.41%
1999 Q3	8 Million USD	14.08%
1999 Q4	8.5 Million USD	16.05%
1999 FY	- USD	40.81%
1998 Q1	3.5 Million USD	-6.67%
1998 Q3	5.6 Million USD	-20.0%
1998 Q4	6.5 Million USD	46.15%
1998 FY	- USD	175.31%
1998 Q2	5.4 Million USD	132.14%
1997 FY	- USD	305.0%
1997 Q3	2.9 Million USD	21.05%
1997 Q4	3.4 Million USD	30.43%
1997 Q1	2 Million USD	50.0%
1997 Q2	2.5 Million USD	111.11%
1996 FY	- USD	-16.67%
1996 Q3	1.3 Million USD	-93.67%
1996 Q4	1.8 Million USD	20.0%
1996 Q1	6.7 Million USD	147.86%
1996 Q2	7.9 Million USD	17.91%
1995 Q2	5.6 Million USD	0.0%
1995 Q3	5.6 Million USD	0.0%
1995 FY	- USD	118.18%
1995 Q4	-14 Million USD	-350.0%
1995 Q1	5.6 Million USD	160.87%
1994 Q4	-9.2 Million USD	-362.86%
1994 FY	- USD	266.67%
1994 Q1	3.5 Million USD	170.0%
1994 Q3	3.5 Million USD	0.0%
1994 Q2	3.5 Million USD	0.0%
1993 Q2	1.9 Million USD	0.0%
1993 FY	- USD	0.0%
1993 Q3	1.9 Million USD	0.0%
1993 Q1	1.9 Million USD	0.0%
1993 Q4	-5 Million USD	-363.16%

Peer EBITDA Comparison of ResMed Inc.

Name	EBITDA	EBITDA Difference
Alcon Inc.	2.39 Billion USD	33.125%
AptarGroup, Inc.	663.83 Million USD	-141.073%
Baxter International Inc.	2.77 Billion USD	42.351%
Becton, Dickinson and Company	2.42 Billion USD	34.007%
Bausch + Lomb Corporation	586 Million USD	-173.094%
Haemonetics Corporation	262.09 Million USD	-510.585%
Envista Holdings Corp	171.1 Million USD	-835.319%
Teleflex Incorporated	792.26 Million USD	-101.996%
Warby Parker Inc.	-30.21 Million USD	5397.001%
West Pharmaceutical Services, Inc.	847.8 Million USD	-88.763%

Global Stocks Search

ResMed Inc. (RMD)

EBITDA Summary of ResMed Inc.

Annual EBITDA Chart of ResMed Inc. (2024 - 1993)

Historical Annual EBITDA of ResMed Inc. (2024 - 1993)

Peer EBITDA Comparison of ResMed Inc.